Update for January 25, 2023

Regulatory Update
 
The FDA approved bexagliflozin (Brenzavvy, TheracosBio), on 1/20/2023, to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
 
The FDA granted granted tecarfarin a Fast Track designation for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. 
 
Finch discontinued the Phase III PRISM4 trial in January 2023, while the company examines the value of its intellectual property estate and other assets. The PRISM4 trial was evaluating CP101 in the prevention of recurrent C. difficile infection.